I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 7 studies | 20% ± 3% | |
| endothelial cell | 5 studies | 24% ± 10% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 20% ± 2% | |
| CD4-positive, alpha-beta T cell | 4 studies | 17% ± 2% | |
| mature NK T cell | 4 studies | 17% ± 2% | |
| CD8-positive, alpha-beta T cell | 4 studies | 22% ± 4% | |
| epithelial cell | 4 studies | 35% ± 12% | |
| ciliated cell | 4 studies | 26% ± 6% | |
| pancreatic A cell | 3 studies | 25% ± 6% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 20% ± 1% | |
| classical monocyte | 3 studies | 25% ± 7% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| non-classical monocyte | 3 studies | 22% ± 6% | |
| mucosal invariant T cell | 3 studies | 18% ± 2% | |
| gamma-delta T cell | 3 studies | 23% ± 8% |
